As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
9 Analysts have issued a Vor Biopharma Inc forecast:
9 Analysts have issued a Vor Biopharma Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -363 -363 |
217%
217%
|
|
| EBIT (Operating Income) EBIT | -367 -367 |
211%
211%
|
|
| Net Profit | -2,450 -2,450 |
2,078%
2,078%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Bob Ang |
| Employees | 154 |
| Founded | 2015 |
| Website | www.vorbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


